Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Open-label, Long-term Study of Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia Who Have Not Reached LDL-cholesterol Target With HMG-CoA Reductase Inhibitors|
- Number of Participants With Adverse Events and Adverse Reactions [ Time Frame: Throughout 1 year of study ]
An adverse event is any unfavorable medical event occurring in a subject to whom an investigational product is administered, and a causal relationship between the administered investigational product and an adverse event is not always clarified.
That is, an adverse event is any unfavorable or unintended sign (including an abnormal change in laboratory test values), symptom, or disease, and a causal relationship to the relevant investigational product is not considered.
Any adverse event that was considered treatment-related was considered an adverse reaction.
|Actual Study Start Date:||December 1, 2007|
|Study Completion Date:||June 1, 2009|
|Primary Completion Date:||June 1, 2009 (Final data collection date for primary outcome measure)|
Experimental: Ezetimibe + Atorvastatin
Ezetimibe 10 mg + Atorvastatin 20 mg
Ezetimibe 10 mg once daily
Other Name: SCH 58235Drug: atorvastatin
atorvastatin 20 mg once daily